The role of lipids and protein kinase Cs in the pathogenesis of diabetic retinopathy

Diabetes/Metabolism Research and Reviews

Volumn 20, Issue 1, 2004, Pages 28-43

  Curtis, T M ^a   Scholfield, C N ^a  

^a QUEEN'S UNIVERSITY BELFAST   (United Kingdom)

Author keywords

Diabetes; Diacylglycerol; Hyperglycemia; Lipids; Microvascular; Protein kinase C; Retinopathy; Vascular

Indexed keywords

1,6 HEXAMETHYLENEDICARBAMIC ACID BIS(CYCLOHEXANONE OXIME) ESTER; 2 [1 (3 AMIDINOTHIOPROPYL) 1H INDOL 3 YL] 3 (1 METHYL 1H INDOL 3 YL)MALEIMIDE; 2 [1 (3 DIMETHYLAMINOPROPYL) 5 METHOXY 1H INDOL 3 YL] 3 (1H INDOL 3 YL)MALEIMIDE; 2,2',3,3',4,4' HEXAHYDROXY 1,1' BIPHENYL 6,6' DIMETHANOL DIMETHYL ETHER; 3 [2 [4 (4,4' DIFLUOROBENZHYDRYLIDENE)PIPERIDINO]ETHYL] 2,3 DIHYDRO 2 THIOXO 4(1H) QUINAZOLINONE; 6 [2 [4 [(4 FLUOROPHENYL)PHENYLMETHYLENE] 1 PIPERIDYL]ETHYL] 7 METHYL 5H THIAZOLO[3,2 A]PYRIMIDIN 5 ONE; 7 HYDROXYSTAUROSPORINE; CALPHOSTIN; DIACYLGLYCEROL; DIACYLGLYCEROL KINASE; DIACYLGLYCEROL KINASE INHIBITOR; FATTY ACID; GLUCOSE; GLYCEROL 3 PHOSPHATE ACYLTRANSFERASE; ISOENZYME; LIPID; LIPOPROTEIN LIPASE; MIDOSTAURIN; OLEIC ACID; PALMITIC ACID; PEPTIDE; PHORBOL ESTER; PROTEIN KINASE C; PROTEIN KINASE C BETA; PROTEIN KINASE C INHIBITOR; RECEPTOR; ROTTLERIN; RU 57908; RUBOXISTAURIN; SAFINGOL; STAUROSPORINE DERIVATIVE; TETRAHYDROLIPSTATIN; UNCLASSIFIED DRUG; UNINDEXED DRUG;

AGE; BLINDNESS; CLINICAL STUDY; CLINICAL TRIAL; DEVELOPED COUNTRY; DIABETES MELLITUS; DIABETIC RETINOPATHY; DOWN REGULATION; DRUG EFFICACY; DRUG RESEARCH; DRUG SPECIFICITY; ENZYME ACTIVATION; ENZYME INHIBITION; EVIDENCE BASED MEDICINE; GLUCOSE BLOOD LEVEL; HIGH RISK POPULATION; HUMAN; HYPERGLYCEMIA; LIPOGENESIS; OXIDATIVE STRESS; PATHOGENESIS; PRIORITY JOURNAL; REVIEW; RISK FACTOR; TOXICITY TESTING; TREATMENT OUTCOME;

ANIMALS; DIABETIC RETINOPATHY; DIGLYCERIDES; HUMANS; HYPERGLYCEMIA; LIPIDS; OXIDATIVE STRESS; PROTEIN KINASE C; RETINAL VESSELS;

EID: 1042291963     PISSN: 15207552     EISSN: None     Source Type: Journal    
DOI: 10.1002/dmrr.431     Document Type: Review

References (214)

1. UK Prospective Diabetes Study (UKPDS) Group. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). Lancet 1998; 352: 837-853.
2. The Diabetes Control and Complications Trial Research Group. The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. N Engl J Med 1993; 329: 977-986.
3. Wei M, Gaskill SP, Haffner SM, et al. Effects of diabetes and level of glycemia on all-cause and cardiovascular mortality. The San Antonio Heart Study. Diabetes Care 1998; 21: 1167-1172.
4. Ebara T, Conde K, Kako Y, et al. Delayed catabolism of apoB-48 lipoproteins due to decreased heparan sulfate proteoglycan production in diabetic mice. J Clin Invest 2000; 105: 1807-1818.
5. Ginsberg HN. Insulin resistance and cardiovascular disease. J Clin Invest 2000; 106: 453-458.
6. Brownlee M. Biochemistry and molecular cell biology of diabetic complications. Nature 2001; 414: 813-820.
7. Pessin MS, Raben DM. Molecular species analysis of 1,2-diglycerides stimulated by alpha- thrombin in cultured fibroblasts. J Biol Chem 1989; 264: 8729-8738.
8. Pettitt TR, Wakelam MJ. Bombesin stimulates distinct time-dependent changes in the sn-1,2- diacylglycerol molecular species profile from Swiss 3T3 fibroblasts as analysed by 3,5-dinitrobenzoyl derivatization and h.p.l.c. separation. Biochem J 1993; 289(Pt 2): 487-495.
9. Hodgkin MN, Pettitt TR, Martin A, et al. Diacylglycerols and phosphatidates: which molecular species are intracellular messengers. Trends Biochem Sci 1998; 23: 200-204.
10. Irvine RF. Nuclear lipid signaling. Sci STKE 2002; 2002: RE13.
11. Lee C, Fisher SK, Agranoff BW, et al. Quantitative analysis of molecular species of diacylglycerol and phosphatidate formed upon muscarinic receptor activation of human SK-N- SH neuroblastoma cells. J Biol Chem 1991; 266: 22 837-22 846.
12. Holbrook PG, Pannell LK, Murata Y, et al. Molecular species analysis of a product of phospholipase D activation. Phosphatidylethanol is formed from phosphatidylcholine in phorbol ester- and bradykinin-stimulated PC12 cells. J Biol Chem 1992; 267: 16 834-16 840.
13. Hermans SW, Engelmann B, Reinhardt U, et al. Diradylglycerol formation in cholecystokinin-stimulated rabbit pancreatic acini. Assessment of precursor phospholipids by means of molecular species analysis. Eur J Biochem 1996; 235: 73-81.
14. Pettitt TR, Zaqqa M, Wakelam MJ. Epidermal growth factor stimulates distinct diradylglycerol species generation in Swiss 3T3 fibroblasts: evidence for a potential phosphatidylcholine-specific phospholipase C-catalysed pathway. Biochem J 1994; 298(Pt 3): 655-660.
15. Pessin MS, Baldassare JJ, Raben DM. Molecular species analysis of mitogen-stimulated 1,2-diglycerides in fibroblasts. Comparison of alpha-thrombin, epidermal growth factor, and platelet-derived growth factor. J Biol Chem 1990; 265: 7959-7966.
16. Newton AC. Protein kinase C: structural and spatial regulation by phosphorylation, cofactors, and macromolecular interactions. Chem Rev 2001; 101: 2353-2364.
17. Oancea E, Meyer T. Protein kinase C as a molecular machine for decoding calcium and diacylglycerol signals. Cell 1998; 95: 307-318.
18. Codazzi F, Teruel MN, Meyer T. Control of astrocyte Ca(2+) oscillations and waves by oscillating translocation and activation of protein kinase C. Curr Biol 2001; 11: 1089-1097.
19. Teruel MN, Meyer T. Parallel single-cell monitoring of receptor-triggered membrane translocation of a calcium-sensing protein module. Science 2002; 295: 1910-1912.
20. Pinton P, Tsuboi T, Ainscow EK, et al. Dynamics of glucose-induced membrane recruitment of protein kinase C bII in living pancreatic islet beta-cells. J Biol Chem 2002; 277: 37 702-37 710.
21. Schechtman D, Mochly-Rosen D. Adaptor proteins in protein kinase C-mediated signal transduction. Oncogene 2001; 20: 6339-6347.
22. Brandon NJ, Uren JM, Kittler JT, et al. Subunit-specific association of protein kinase C and the receptor for activated C kinase with GABA type A receptors. J Neurosci 1999; 19: 9228-9234.
23. Brooks G, Evans AT, Aitken A, et al. Sapintoxin A. A fluorescent phorbol ester that is a potent activator of protein kinase C but is not a tumour promoter. Cancer Lett 1987; 38: 165-170.
24. Ryves WJ, Evans AT, Olivier AR, et al. Activation of the PKC-isotypes alpha, beta 1, gamma, delta and epsilon by phorbol esters of different biological activities. FEBS Lett 1991; 288: 5-9.
25. Kazanietz MG. Eyes wide shut: protein kinase C isozymes are not the only receptors for the phorbol ester tumor promoters. Mol Carcinog 2000; 28: 5-11.
26. Garcia-Bermejo ML, Leskow FC, Fujii T, et al. Diacylglycerol (DAG)-lactones, a new class of protein kinase C (PKC) agonists, induce apoptosis in LNCaP prostate cancer cells by selective activation of PKCalpha. J Biol Chem 2002; 277: 645-655.
27. Irie K, Nakahara A, Nakagawa Y, et al. Establishment of a binding assay for protein kinase C isozymes using synthetic C1 peptides and development of new medicinal leads with protein kinase C isozyme and C1 domain selectivity. Pharmacol Ther 2002; 93: 271.
28. Kiss Z, Deli E, Shoji M, et al. Differential effects of various protein kinase C activators on protein phosphorylation in human acute myeloblastic leukemia cell line KG-1 and its phorbol ester-resistant subline KG-1a. Cancer Res 1987; 47: 1302-1307.
29. Kotsonis P, Funk L, Prountzos C, et al. Differential abilities of phorbol esters in inducing protein kinase C (PKC) down-regulation in noradrenergic neurones. Br J Pharmacol 2001; 132: 489-499.
30. Wang QJ, Bhattacharyya D, Garfield S, et al. Differential localization of protein kinase C delta by phorbol esters and related compounds using a fusion protein with green fluorescent protein. J Biol Chem 1999; 274: 37 233-37 239.
31. Pettitt TR, Martin A, Horton T, et al. Diacylglycerol and phosphatidate generated by phospholipases C and D, respectively, have distinct fatty acid compositions and functions. Phospholipase D-derived diacylglycerol does not activate protein kinase C in porcine aortic endothelial cells. J Biol Chem 1997; 272: 17 354-17 359.
32. Madani S, Hichami A, Legrand A, et al. Implication of acyl chain of diacylglycerols in activation of different isoforms of protein kinase C. FASEB J 2001; 15: 2595-2601.
33. Qiao L, Zhao LY, Rong SB, et al. Rational design, synthesis, and biological evaluation of rigid pyrrolidone analogues as potential inhibitors of prostate cancer cell growth. Bioorg Med Chem Lett 2001; 11: 955-959.
34. Parang K, Cole P. Designing bisubstrate analog inhibitors for protein kinases. Pharmacol Ther 2002; 93: 145.
35. Harris TE, Persaud SJ, Jones PM. Pseudosubstrate peptide inhibitors of beta-cell protein kinases: altered selectivity after myristoylation. Mol Cell Endocrinol 1999; 155: 61-68.
36. Kanoh H, Yamada K, Sakane F. Diacylglycerol kinases: emerging downstream regulators in cell signaling systems. J Biochem (Tokyo) 2002; 131: 629-633.
37. Ohanian J, Ohanian V. Lipid second messenger regulation: the role of diacylglycerol kinases and their relevance to hypertension. J Hum Hypertens 2001; 15: 93-98.
38. Topham MK, Prescott SM. Mammalian diacylglycerol kinases, a family of lipid kinases with signaling functions. J Biol Chem 1999; 274: 11 447-11 450.
39. van Blitterswijk WJ, Houssa B. Properties and functions of diacylglycerol kinases. Cell Signal 2000; 12: 595-605.
40. Pettitt TR, Wakelam MJ. Diacylglycerol kinase epsilon, but not zeta, selectively removes polyunsaturated diacylglycerol, inducing altered protein kinase C distribution in vivo. J Biol Chem 1999; 274: 36 181-36 186.
41. Tang W, Bunting M, Zimmerman GA, et al. Molecular cloning of a novel human diacylglycerol kinase highly selective for arachidonate-containing substrates. J Biol Chem 1996; 271: 10 237-10 241.
42. Jiang Y, Sakane F, Kanoh H, et al. Selectivity of the diacylglycerol kinase inhibitor 3-[2-(4-[bis-(4-fluorophenyl)methylene]-1-piperidinyl)ethyl]-2, 3-dihydro-2-thioxo-4(1H)quinazolinone (R59949) among diacylglycerol kinase subtypes. Biochem Pharmacol 2000; 59: 763-772.
43. Du X, Jiang Y, Qian W, et al. Fatty acids inhibit growth-factor-induced diacylglycerol kinase alpha activation in vascular smooth-muscle cells. Biochem J 2001; 357: 275-282.
44. Luo B, Prescott SM, Topham MK. Protein kinase C alpha phosphorylates and negatively regulates diacylglycerol kinase zeta. J Biol Chem 2003; 160: 929-937.
45. Yamada K, Sakane F, Imai S, et al. Regulatory role of diacylglycerol kinase gamma in macrophage differentiation of leukemia cells. Biochem Biophys Res Commun 2003; 305: 101-107.
46. Nobe K, Sakai Y, Momose K. Alternations of diacylglycerol kinase in streptozotocin-induced diabetic rats. Cell Signal 1998; 10: 465-471.
47. Moriyama T, Urade R, Kito M. Purification and characterization of diacylglycerol lipase from human platelets. J Biochem (Tokyo) 1999; 125: 1077-1085.
48. Authi KS, Lagarde M, Crawford N. Diacylglycerol lipase activity in human platelet intracellular and surface membranes. Some kinetic properties and fatty acid specificity. FEBS Lett 1985; 180: 95-101.
49. Severson DL, Hee-Cheong M. Diacylglycerol lipase and kinase activities in rabbit aorta and coronary microvessels. Biochem Cell Biol 1986; 64: 976-983.
50. Xia T, Coleman RA. Diacylglycerol metabolism in neonatal rat liver: characterization of cytosolic diacylglycerol lipase activity and its activation by monoalkylglycerols. Biochim Biophys Acta 1992; 1126: 327-336.
51. Chuang M, Lee MW, Zhao D, et al. Metabolism of a long-chain diacylglycerol by permeabilized A10 smooth muscle cells. Am J Physiol 1993; 265: C927-C933.
52. Hee-Cheong M, Fletcher T, Kryski SK, et al. Diacylglycerol lipase and kinase activities in rat brain microvessels. Biochim Biophys Acta 1985; 833: 59-68.
53. Lee MW, Severson DL. Partial purification of a diacylglycerol lipase from bovine aorta. Biochem J 1994; 298(Pt 1): 213-219.
54. Migas I, Chuang M, Sasaki Y, et al. Diacylglycerol metabolism in SM-3 smooth muscle cells. Can J Physiol Pharmacol 1997; 75: 1249-1256.
55. Farooqui AA, Anderson DK, Flynn C, et al. Stimulation of mono- and diacylglycerol lipase activities by bradykinin in neural cultures. Biochem Biophys Res Commun 1990; 166: 1001-1009.
56. Freysz L, Farooqui AA, Horrocks LA, et al. Stimulation of mono- and diacylglycerol lipase activities by gangliosides in chicken neuronal cultures. Neurochem Res 1991; 16: 1241-1244.
57. Capito K, Hansen SE, Hedeskov CJ, et al. Effect of diacylglycerol lipase inhibitor RHC 80267 on pancreatic mouse islet metabolism and insulin secretion. Diabetologia 1989; 32: 111-117.
58. Rindlisbacher B, Sidler MA, Galatioto LE, et al. Arachidonic acid liberated by diacylglycerol lipase is essential for the release mechanism in chromaffin cells from bovine adrenal medulla. J Neurochem 1990; 54: 1247-1252.
59. Yang SG, Saifeddine M, Chuang M, et al. Diacylglycerol lipase and the contractile action of epidermal growth factor-urogastrone: evidence for distinct signal pathways in a single strip of gastric smooth muscle. Eur J Pharmacol 1991; 207: 225-230.
60. Igal RA, Caviglia JM, de GD, et al. Diacylglycerol generated in CHO cell plasma membrane by phospholipase C is used for triacylglycerol synthesis. J Lipid Res 2001; 42: 88-95.
61. Shiba T, Inoguchi T, Sportsman JR, et al. Correlation of diacylglycerol level and protein kinase C activity in rat retina to retinal circulation. Am J Physiol 1993; 265: E783-E793.
62. Inoguchi T, Battan R, Handler E, et al. Preferential elevation of protein kinase C isoform beta II and diacylglycerol levels in the aorta and heart of diabetic rats: differential reversibility to glycemic control by islet cell transplantation. Proc Natl Acad Sci U S A 1992; 89: 11 059-11 063.
63. Craven PA, Davidson CM, DeRubertis FR. Increase in diacylglycerol mass in isolated glomeruli by glucose from de novo synthesis of glycerolipids. Diabetes 1990; 39: 667-674.
64. Ido Y, McHowat J, Chang KC, et al. Neural dysfunction and metabolic imbalances in diabetic rats. Prevention by acetyl-L-carnitine. Diabetes 1994; 43: 1469-1477.
65. Xia P, Inoguchi T, Kern TS, et al. Characterization of the mechanism for the chronic activation of diacylglycerol-protein kinase C pathway in diabetes and hypergalactosemia. Diabetes 1994; 43: 1122-1129.
66. Inoguchi T, Xia P, Kunisaki M, et al. Insulin's effect on protein kinase C and diacylglycerol induced by diabetes and glucose in vascular tissues. Am J Physiol 1994; 267: E369-E379.
67. Engerman RL, Kern TS. Progression of incipient diabetic retinopathy during good glycemic control. Diabetes 1987; 36: 808-812.
68. Ayo SH, Radnik R, Garoni JA, et al. High glucose increases diacylglycerol mass and activates protein kinase C in mesangial cell cultures. Am J Physiol 1991; 261: F571-F577.
69. Nishikawa T, Edelstein D, Brownlee M. The missing link: a single unifying mechanism for diabetic complications. Kidney Int Suppl 2000; 77: S26-S30.
70. Yoshida K, Hirokawa J, Tagami S, et al. Weakened cellular scavenging activity against oxidative stress in diabetes mellitus: regulation of glutathione synthesis and efflux. Diabetologia 1995; 38: 201-210.
71. Chen MS, Hutchinson ML, Pecoraro RE, et al. Hyperglycemia-induced intracellular depletion of ascorbic acid in human mononuclear leukocytes. Diabetes 1983; 32: 1078-1081.
72. Karpen CW, Cataland S, O'Dorisio TM, et al. Production of 12-hydroxyeicosatetraenoic acid and vitamin E status in platelets from type I human diabetic subjects. Diabetes 1985; 34: 526-531.
73. Ono Y, Aoki S, Ohnishi K, et al. Increased serum levels of advanced glycation end-products and diabetic complications. Diabetes Res Clin Pract 1998; 41: 131-137.
74. Aso Y, Inukai T, Tayama K, et al. Serum concentrations of advanced glycation endproducts are associated with the development of atherosclerosis as well as diabetic microangiopathy in patients with type 2 diabetes. Acta Diabetol 2000; 37: 87-92.
75. Horie K, Miyata T, Maeda K, et al. Immunohistochemical colocalization of glycoxidation products and lipid peroxidation products in diabetic renal glomerular lesions. Implication for glycoxidative stress in the pathogenesis of diabetic nephropathy. J Clin Invest 1997; 100: 2995-3004.
76. Stitt AW, Li YM, Gardiner TA, et al. Advanced glycation end products (AGEs) co-localize with AGE receptors in the retinal vasculature of diabetic and of AGE-infused rats. Am J Pathol 1997; 150: 523-531.
77. Wolff SP, Dean RT. Glucose autoxidation and protein modification. The potential role of 'autoxidative glycosylation' in diabetes. Biochem J 1987; 245: 243-250.
78. Baynes JW, Thorpe SR. Role of oxidative stress in diabetic complications: a new perspective on an old paradigm. Diabetes 1999; 48: 1-9.
79. Yan SD, Schmidt AM, Anderson GM, et al. Enhanced cellular oxidant stress by the interaction of advanced glycation end products with their receptors/binding proteins. J Biol Chem 1994; 269: 9889-9897.
80. Gopalakrishna R, Anderson WB. Ca2+- and phospholipid-independent activation of protein kinase C by selective oxidative modification of the regulatory domain. Proc Natl Acad Sci USA 1989; 86: 6758-6762.
81. Palumbo EJ, Sweatt JD, Chen SJ, et al. Oxidation-induced persistent activation of protein kinase C in hippocampal homogenates. Biochem Biophys Res Commun 1992; 187: 1439-1445.
82. Brawn MK, Chiou WJ, Leach KL. Oxidant-induced activation of protein kinase C in UC11MG cells. Free Radical Res 1995; 22: 23-37.
83. Whisler RL, Goyette MA, Grants IS, et al. Sublethal levels of oxidant stress stimulate multiple serine/threonine kinases and suppress protein phosphatases in Jurkat T cells. Arch Biochem Biophys 1995; 319: 23-35.
84. Kowluru RA. Diabetes-induced elevations in retinal oxidative stress, protein kinase C and nitric oxide are interrelated. Acta Diabetol 2001; 38: 179-185.
85. Ha H, Yu MR, Choi YJ, et al. Activation of protein kinase c-delta and c-epsilon by oxidative stress in early diabetic rat kidney. Am J Kidney Dis 2001; 38: S204-S207.
86. Scivittaro V, Ganz MB, Weiss MF. AGEs induce oxidative stress and activate protein kinase C-beta(II) in neonatal mesangial cells. Am J Physiol Renal Physiol 2000; 278: F676-F683.
87. Ido Y, Chang KC, Lejeune WS, et al. Vascular dysfunction induced by AGE is mediated by VEGF via mechanisms involving reactive oxygen species, guanylate cyclase, and protein kinase C. Microcirculation 2001; 8: 251-263.
88. Mamputu JC, Renier G. Advanced glycation end products increase, through a protein kinase C- dependent pathway, vascular endothelial growth factor expression in retinal endothelial cells. Inhibitory effect of gliclazide. J Diabetes Complications 2002; 16: 284-293.
89. Konishi H, Tanaka M, Takemura Y, et al. Activation of protein kinase C by tyrosine phosphorylation in response to H2O2. Proc Natl Acad Sci U S A 1997; 94: 11 233-11 237.
90. Konishi H, Yamauchi E, Taniguchi H, et al. Phosphorylation sites of protein kinase C delta in H2O2-treated cells and its activation by tyrosine kinase in vitro. Proc Natl Acad Sci U S A 2001; 98: 6587-6592.
91. Yamamoto T, Matsuzaki H, Konishi H, et al. H(2)O(2)-induced tyrosine phosphorylation of protein kinase cdelta by a mechanism independent of inhibition of protein-tyrosine phosphatase in CHO and COS-7 cells. Biochem Biophys Res Commun 2000; 273: 960-966.
92. Gopalakrishna R, Jaken S. Protein kinase C signaling and oxidative stress. Free Radical Biol Med 2000; 28: 1349-1361.
93. Inoguchi T, Sonta T, Tsubouchi H, et al. Protein kinase C-dependent increase in reactive oxygen species (ROS) production in vascular tissues of diabetes: role of vascular NAD(P)H oxidase. J Am Soc Nephrol 2003; 14: S227-232.
94. Trevisan R, Nosadini R, Avogaro A, et al. Type I diabetes is characterized by insulin resistance not only with regard to glucose, but also to lipid and amino acid metabolism. J Clin Endocrinol Metab 1986; 62: 1155-1162.
95. Reaven GM, Hollenbeck C, Jeng CY, et al. Measurement of plasma glucose, free fatty acid, lactate, and insulin for 24 h in patients with NIDDM. Diabetes 1988; 37: 1020-1024.
96. Taskinen MR, Bogardus C, Kennedy A, et al. Multiple disturbances of free fatty acid metabolism in noninsulin-dependent diabetes. Effect of oral hypoglycemic therapy. J Clin Invest 1985; 76: 637-644.
97. Lu X, Yang XY, Howard RL, et al. Fatty acids modulate protein kinase C activation in porcine vascular smooth muscle cells independently of their effect on de novo diacylglycerol synthesis. Diabetologia 2000; 43: 1136-1144.
98. Unger RH, Zhou YT. Lipotoxicity of beta-cells in obesity and in other causes of fatty acid spillover. Diabetes 2001; 50: (Suppl. 1) : S118-S121.
99. Schmitz-Peiffer C. Protein kinase C and lipid-induced insulin resistance in skeletal muscle. Ann N Y Acad Sci 2002; 967: 146-157.
100. Farese RV. Function and dysfunction of aPKC isoforms for glucose transport in insulin-sensitive and insulin-resistant states. Am J Physiol Endocrinol Metab 2002; 283: E1-E11.
101. Schaffer JE. Lipotoxicity: when tissues overeat. Curr Opin Lipidol 2003; 14: 281-287.
102. Idel S, Ellinghaus P, Wolfrum C, et al. Branched chain fatty acids induce nitric oxide-dependent apoptosis in vascular smooth muscle cells. J Biol Chem 2002; 277: 49 319-49 325.
103. Hamilton JS, Powell LA, McMaster C, et al. Interaction of glucose and long chain fatty acids (C18) on antioxidant defences and free radical damage in porcine vascular smooth muscle cells in vitro. Diabetologia 2003; 46: 106-114.
104. McPhail LC, Clayton CC, Snyderman R. A potential second messenger role for unsaturated fatty acids: activation of Ca2+-dependent protein kinase. Science 1984; 224: 622-625.
105. el Touny S, Khan W, Hannun Y. Regulation of platelet protein kinase C by oleic acid. Kinetic analysis of allosteric regulation and effects on autophosphorylation, phorbol ester binding, and susceptibility to inhibition. J Biol Chem 1990; 265: 16 437-16 443.
106. Khan WA, Blobe GC, Hannun YA. Arachidonic acid and free fatty acids as second messengers and the role of protein kinase C. Cell Signal 1995; 7: 171-184.
107. Muzzio IA, Gandhi CC, Manyam U, et al. Receptor-stimulated phospholipase A(2) liberates arachidonic acid and regulates neuronal excitability through protein kinase C. J Neurophysiol 2001; 85: 1639-1647.
108. Yaney GC, Korchak HM, Corkey BE. Long-chain acyl CoA regulation of protein kinase C and fatty acid potentiation of glucose-stimulated insulin secretion in clonal beta-cells. Endocrinology 2000; 141: 1989-1998.
109. Padma M, Das UN. Effect of cis-unsaturated fatty acids on the activity of protein kinases and protein phosphorylation in macrophage tumor (AK-5) cells in vitro. Prostaglandins Leukot Essent Fatty Acids 1999; 60: 55-63.
110. Lee HW, Smith L, Pettit GR, et al. Bryostatin 1 and phorbol ester down-modulate protein kinase C-alpha and -epsilon via the ubiquitin/proteasome pathway in human fibroblasts. Mol Pharmacol 1997; 51: 439-447.
111. Lu Z, Liu D, Hornia A, et al. Activation of protein kinase C triggers its ubiquitination and degradation. Mol Cell Biol 1998; 18: 839-845.
112. Junoy B, Maccario H, Mas JL, et al. Proteasome implication in phorbol ester- and GnRH-induced selective down-regulation of PKC (alpha, epsilon, zeta) in alpha T(3)-1 and L beta T(2) gonadotrope cell lines. Endocrinology 2002; 143: 1386-1403.
113. White MF. IRS proteins and the common path to diabetes. Am J Physiol Endocrinol Metab 2002; 283: E413-E422.
114. Cui SH, Tanabe F, Terunuma H, et al. A thiol proteinase inhibitor, E-64-d, corrects the abnormalities in concanavalin A cap formation and the lysosomal enzyme activity in leucocytes from patients with Chediak-Higashi syndrome by reversing the down-regulated protein kinase C activity. Clin Exp Immunol 2001; 125: 283-290.
115. Gao T, Newton AC. The turn motif is a phosphorylation switch that regulates the binding of hsp70 to protein kinase C. J Biol Chem 2002; 277: 31 585-31 592.
116. Suzuki K, Saido TC, Hirai S. Modulation of cellular signals by calpain. Ann N Y Acad Sci 1992; 674: 218-227.
117. Hong DH, Huan J, Ou BR, et al. Protein kinase C isoforms in muscle cells and their regulation by phorbol ester and calpain. Biochim Biophys Acta 1995; 1267: 45-54.
118. Lang D, Beermann ML, Hauser G, et al. Phospholipids inhibit proteolysis of protein kinase C alpha by mM calcium-requiring calpain. Neurochem Res 1995; 20: 1361-1364.
119. Shore AC, Evans JC, Frayling TM, et al. Calpain 10 and microvascular function. Diabetologia 2002; 45: 899-904.
120. Sato M, Tani E, Matsumoto T, et al. Generation of the catalytic fragment of protein kinase C alpha in spastic canine basilar artery. J Neurosurg 1997; 87: 752-756.
121. Aiello LP, Gardner TW, King GL, et al. Diabetic retinopathy. Diabetes Care 1998; 21: 143-156.
122. Klein R, Klein BE, Moss SE. The Wisconsin epidemiological study of diabetic retinopathy: a review. Diabetes Metab Rev 1989; 5: 559-570.
123. Lorenzi M, Gerhardinger C. Early cellular and molecular changes induced by diabetes in the retina. Diabetologia 2001; 44: 791-804.
124. Simonsen S. ERG in diabetics. In The Clinical Value of Electroretinography, Karger: New York, 1968; 403-412.
125. Ghirlanda G, Di Leo MA, Caputo S, et al. From functional to microvascular abnormalities in early diabetic retinopathy. Diabetes Metab Rev 1997; 13: 15-35.
126. Parisi V, Uccioli L, Parisi L, et al. Neural conduction in visual pathways in newly-diagnosed IDDM patients. Electroencephalogr Clin Neurophysiol 1998; 108: 490-496.
127. Schmetterer L, Wolzt M. Ocular blood flow and associated functional deviations in diabetic retinopathy. Diabetologia 1999; 42: 387-405.
128. Cunha-Vaz J, Faria A Jr., Campos AJ. Early breakdown of the blood-retinal barrier in diabetes. Br J Ophthalmol 1975; 59: 649-656.
129. Do carmo A, Ramos P, Reis A, et al. Breakdown of the inner and outer blood retinal barrier in streptozotocin-induced diabetes. Exp Eye Res 1998; 67: 569-575.
130. Kohner EM, Patel V, Rassam SM. Role of blood flow and impaired autoregulation in the pathogenesis of diabetic retinopathy. Diabetes 1995; 44: 603-607.
131. Friedenwald JS. Diabetic Retinopathy. Am J Ophthal 1950; 33: 1187-1199.
132. Kuwabara T, Cogan DG. Retinal Vascular Patterns. VI. Mural Cells of the retinal capillaries. Arch Ophthalmol 1963; 69: 492-502.
133. Gardiner TA, Stitt AW, Anderson HR, et al. Selective loss of vascular smooth muscle cells in the retinal microcirculation of diabetic dogs. Br J Ophthalmol 1994; 78: 54-60.
134. Bresnick GH, Davis MD, Myers FL, et al. Clinicopathologic correlations in diabetic retinopathy. II. Clinical and histologic appearances of retinal capillary microaneurysms. Arch Ophthalmol 1977; 95: 1215-1220.
135. Engerman RL. Pathogenesis of diabetic retinopathy. Diabetes 1989; 38: 1203-1206.
136. Kohner EM, Henkind P. Correlation of fluorescein angiogram and retinal digest in diabetic retinopathy. Am J Ophthalmol 1970; 69: 403-414.
137. Aiello LP, Avery RL, Arrigg PG, et al. Vascular endothelial growth factor in ocular fluid of patients with diabetic retinopathy and other retinal disorders. N Engl J Med 1994; 331: 1480-1487.
138. Khaliq A, Foreman D, Ahmed A, et al. Increased expression of placenta growth factor in proliferative diabetic retinopathy. Lab Invest 1998; 78: 109-116.
139. Dawson DW, Volpert OV, Gillis P, et al. Pigment epithelium-derived factor: a potent inhibitor of angiogenesis. Science 1999; 285: 245-248.
140. Cai J, Boulton M. The pathogenesis of diabetic retinopathy: old concepts and new questions. Eye 2002; 16: 242-260.
141. Wood JP, McCord RJ, Osborne NN. Retinal protein kinase C. Neurochem Int 1997; 30: 119-136.
142. Gabriel R, Lesauter J, Silver R, et al. Diurnal and circadian variation of protein kinase C immunoreactivity in the rat retina. J Comp Neurol 2001; 439: 140-150.
143. Park JY, Takahara N, Gabriele A, et al. Induction of endothelin-1 expression by glucose: an effect of protein kinase C activation. Diabetes 2000; 49: 1239-1248.
144. Kohner EM, Hamilton AM, Saunders SJ, et al. The retinal blood flow in diabetes. Diabetologia 1975; 11: 27-33.
145. Yu DY, Su EN, Cringle SJ, et al. Isolated preparations of ocular vasculature and their applications in ophthalmic research. Prog Retin Eye Res 2003; 22: 135-169.
146. Grunwald JE, Riva CE, Baine J, et al. Total retinal volumetric blood flow rate in diabetic patients with poor glycemic control. Invest Ophthalmol Vis Sci 1992; 33: 356-363.
147. Patel V, Rassam S, Newsom R, et al. Retinal blood flow in diabetic retinopathy. BMJ 1992; 305: 678-683.
148. Grunwald JE, DuPont J, Riva CE. Retinal haemodynamics in patients with early diabetes mellitus. Br J Ophthalmol 1996; 80: 327-331.
149. Grunwald JE, Brucker AJ, Grunwald SE, et al. Retinal hemodynamics in proliferative diabetic retinopathy. A laser Doppler velocimetry study. Invest Ophthalmol Vis Sci 1993; 34: 66-71.
150. Takagi C, Bursell SE, Lin YW, et al. Regulation of retinal hemodynamics in diabetic rats by increased expression and action of endothelin-1. Invest Ophthalmol Vis Sci 1996; 37: 2504-2518.
151. Scholfield CN, Curtis TM. Heterogeneity in cytosolic calcium regulation among different microvascular smooth muscle cells of the rat retina. Microvasc Res 2000; 59: 233-242.
152. Schiffrin EL, Touyz RM. Vascular biology of endothelin. J Cardiovasc Pharmacol 1998; 32: (Suppl. 3) : S2-S13.
153. Curtis TM, Scholfield CN. Attenuated endothelin responses in retinal microvessels from diabetic rats. J Physiol 1999; 515P, 6P.
154. Awazu M, Parker RE, Harvie BR, et al. Down-regulation of endothelin-1 receptors by protein kinase C in streptozotocin diabetic rats. J Cardiovasc Pharmacol 1991; 17: (Suppl. 7) : S500-S502.
155. Makino A, Kamata K. Elevated plasma endothelin-1 level in streptozotocin-induced diabetic rats and responsiveness of the mesenteric arterial bed to endothelin-1. Br J Pharmacol 1998; 123: 1065-1072.
156. Chakravarthy U, Hayes RG, Stitt AW, et al. Endothelin expression in ocular tissues of diabetic and insulin-treated rats. Invest Ophthalmol Vis Sci 1997; 38: 2144-2151.
157. Deng D, Evans T, Mukherjee K, et al. Diabetes-induced vascular dysfunction in the retina: role of endothelins. Diabetologia 1999; 42: 1228-1234.
158. Yokota T, Ma RC, Park JY, et al. Role of protein kinase C on the expression of platelet-derived growth factor and endothelin-1 in the retina of diabetic rats and cultured retinal capillary pericytes. Diabetes 2003; 52: 838-843.
159. Palmer RM, Ashton DS, Moncada S. Vascular endothelial cells synthesize nitric oxide from L-arginine. Nature 1988; 333: 664-666.
160. Koss MC. Functional role of nitric oxide in regulation of ocular blood flow. Eur J Pharmacol 1999; 374: 161-174.
161. Carmo A, Cunha-vaz JG, Carvalho AP, et al. Nitric oxide synthase activity in retinas from non-insulin-dependent diabetic Goto-Kakizaki rats: correlation with blood-retinal barrier permeability. Nitric Oxide 2000; 4: 590-596.
162. Takeda M, Mori F, Yoshida A, et al. Constitutive nitric oxide synthase is associated with retinal vascular permeability in early diabetic rats. Diabetologia 2001; 44: 1043-1050.
163. Abu EI-Asrar AM, Desmet S, Meersschaert A, et al. Expression of the inducible isoform of nitric oxide synthase in the retinas of human subjects with diabetes mellitus. Am J Ophthalmol 2001; 132: 551-556.
164. Johnson EI, Dunlop ME, Larkins RG. Increased vasodilatory prostaglandin production in the diabetic rat retinal vasculature. Curr Eye Res 1999; 18: 79-82.
165. Hata Y, Clermont A, Yamauchi T, et al. Retinal expression, regulation, and functional bioactivity of prostacyclin-stimulating factor. J Clin Invest 2000; 106: 541-550.
166. Hashimoto T, Imamura M, Etoh T, et al. Lysophosphatidyl-choline inhibits the expression of prostacyclin stimulating factor in cultured vascular smooth muscle cells. J Diabetes Complications 2002; 16: 81-86.
167. Curtis TM, Major EH, Trimble ER, et al. Diabetes-induced activation of protein kinase C inhibits store-operated Ca(2+) uptake in rat retinal microvascular smooth muscle. Diabetologia 2003; 46(9): 1252-1259.
168. Takagi C, King GL, Clermont AC, et al. Reversal of abnormal retinal hemodynamics in diabetic rats by acarbose, an alpha-glucosidase inhibitor. Curr Eye Res 1995; 14: 741-749.
169. Ishii H, Jirousek MR, Koya D, et al. Amelioration of vascular dysfunctions in diabetic rats by an oral PKC beta inhibitor. Science 1996; 272: 728-731.
170. Bursell SE, Takagi C, Clermont AC, et al. Specific retinal diacylglycerol and protein kinase C beta isoform modulation mimics abnormal retinal hemodynamics in diabetic rats. Invest Ophthalmol Vis Sci 1997; 38: 2711-2720.
171. Koronkiewicz S, Kalinowski S, Bryl K. Changes of structural and dynamic properties of model lipid membranes induced by alpha-tocopherol: implication to the membrane stabilization under external electric field. Biochim Biophys Acta 2001; 1510: 300-306.
172. Koya D, Lee IK, Ishii H, et al. Prevention of glomerular dysfunction in diabetic rats by treatment with d-alpha-tocopherol. J Am Soc Nephrol 1997; 8: 426-435.
173. Schroder S, Palinski W, Schmid-Schonbein GW. Activated monocytes and granulocytes, capillary nonperfusion, and neovascularization in diabetic retinopathy. Am J Pathol 1991; 139: 81-100.
174. McLeod DS, Lefer DJ, Merges C, et al. Enhanced expression of intracellular adhesion molecule-1 and P-selectin in the diabetic human retina and choroid. Am J Pathol 1995; 147: 642-653.
175. Nonaka A, Kiryu J, Tsujikawa A, et al. PKC-beta inhibitor (LY333531) attenuates leukocyte entrapment in retinal microcirculation of diabetic rats. Invest Ophthalmol Vis Sci 2000; 41: 2702-2706.
176. Abiko T, Abiko A, Clermont AC, et al. Characterization of retinal leukostasis and hemodynamics in insulin resistance and diabetes: role of oxidants and protein kinase-C activation. Diabetes 2003; 52: 829-837.
177. Enea NA, Hollis TM, Kern JA, et al. Histamine H1 receptors mediate increased blood-retinal barrier permeability in experimental diabetes. Arch Ophthalmol 1989; 107: 270-274.
178. Stasek JE Jr., Patterson CE, Garcia JG. Protein kinase C phosphorylates caldesmon77 and vimentin and enhances albumin permeability across cultured bovine pulmonary artery endothelial cell monolayers. J Cell Physiol 1992; 153: 62-75.
179. Clarke H, Marano CW, Peralta SA, et al. Modification of tight junction function by protein kinase C isoforms. Adv Drug Deliv Rev 2000; 41: 283-301.
180. Nitta K, Horiba N, Uchida K, et al. High glucose modulates albumin permeability across glomerular endothelial cells via a protein kinase C-dependent mechanism. Nippon Jinzo Gakkai Shi 1995; 37: 317-322.
181. Hempel A, Maasch C, Heintze U, et al. High glucose concentrations increase endothelial cell permeability via activation of protein kinase C alpha. Circ Res 1997; 81: 363-371.
182. Nagpala PG, Malik AB, Vuong PT, et al. Protein kinase C beta 1 overexpression augments phorbol ester-induced increase in endothelial permeability. J Cell Physiol 1996; 166: 249-255.
183. Yuan SY, Ustinova EE, Wu MH, et al. Protein kinase C activation contributes to microvascular barrier dysfunction in the heart at early stages of diabetes. Circ Res 2000; 87: 412-417.
184. Clermont A, Salti LE, Goddard LE, et al. Diabetes-induced retinal vascular permeability is both prevented and reversed in vivo by oral administration of a PKCbeta-selective inhibitor LY333531. Association for Research in Vision and Ophthalmology (May 2002); Abstract 38632002.
185. Mayhan WG. Role of nitric oxide in modulating permeability of hamster cheek pouch in response to adenosine 5′-diphosphate and bradykinin. Inflammation 1992; 16: 295-305.
186. Meyer DJ Jr., Huxley VH. Capillary hydraulic conductivity is elevated by cGMP-dependent vasodilators. Circ Res 1992; 70: 382-391.
187. Huang Q, Yuan Y. Interaction of PKC and NOS in signal transduction of microvascular hyperpermeability. Am J Physiol 1997; 273: H2442-H2451.
188. Chen S, Apostolova MD, Cherian MG, et al. Interaction of endothelin-1 with vasoactive factors in mediating glucose-induced increased permeability in endothelial cells. Lab Invest 2000; 80: 1311-1321.
189. Fantone JC, Kunkel SL, Ward PA, et al. Suppression by prostaglandin E1 of vascular permeability induced by vasoactive inflammatory mediators. J Immunol 1980; 125: 2591-2596.
190. Gee MH, Tahamont MV, Flynn JT, et al. Prostaglandin E1 prevents increased lung microvascular permeability during intravascular complement activation in sheep. Circ Res 1987; 61: 420-428.
191. Jiang XW, Kambara K, Gotoh N, et al. Effects of low-dose Beraprost sodium, a stable prostaglandin I2 analogue, on reperfusion injury to rabbit lungs. Am J Respir Crit Care Med 1998; 158: 1669-1675.
192. Farmer PJ, Bernier SG, Lepage A, et al. Permeability of endothelial monolayers to albumin is increased by bradykinin and inhibited by prostaglandins. Am J Physiol Lung Cell Mol Physiol 2001; 280: L732-L738.
193. Kajimura M, Michel CC. Inhibition of effects of flow on potassium permeability in single perfused frog mesenteric capillaries. J Physiol 1999; 516(Pt 1): 201-207.
194. Montermini D, Winlove CP, Michel C. Effects of perfusion rate on permeability of frog and rat mesenteric microvessels to sodium fluorescein. J Physiol 2002; 543: 959-975.
195. Sone H, Kawakami Y, Okuda Y, et al. Ocular vascular endothelial growth factor levels in diabetic rats are elevated before observable retinal proliferative changes. Diabetologia 1997; 40: 726-730.
196. Murata T, Nakagawa K, Khalil A, et al. The relation between expression of vascular endothelial growth factor and breakdown of the blood-retinal barrier in diabetic rat retinas. Lab Invest 1996; 74: 819-825.
197. Tang J, Zhu XW, Lust WD, et al. Retina accumulates more glucose than does the embryologically similar cerebral cortex in diabetic rats. Diabetologia 2000; 43: 1417-1423.
198. Williams B, Gallacher B, Patel H, et al. Glucose-induced protein kinase C activation regulates vascular permeability factor mRNA expression and peptide production by human vascular smooth muscle cells in vitro. Diabetes 1997; 46: 1497-1503.
199. Kim NH, Jung HH, Cha DR, et al. Expression of vascular endothelial growth factor in response to high glucose in rat mesangial cells. J Endocrinol 2000; 165: 617-624.
200. Hoshi S, Nomoto K, Kuromitsu J, et al. High glucose induced VEGF expression via PKC and ERK in glomerular podocytes. Biochem Biophys Res Commun 2002; 290: 177-184.
201. Liu LX, Lu H, Luo Y, et al. Stabilization of vascular endothelial growth factor mRNA by hypoxia- inducible factor 1. Biochem Biophys Res Commun 2002; 291: 908-914.
202. Levy NS, Chung S, Furneaux H, et al. Hypoxic stabilization of vascular endothelial growth factor mRNA by the RNA-binding protein HuR. J Biol Chem 1998; 273: 6417-6423.
203. Shih SC, Claffey KP. Regulation of human vascular endothelial growth factor mRNA stability in hypoxia by heterogeneous nuclear ribonucleoprotein L. J Biol Chem 1999; 274: 1359-1365.
204. Zachary I, Gliki G. Signaling transduction mechanisms mediating biological actions of the vascular endothelial growth factor family. Cardiovasc Res 2001; 49: 568-581.
205. Xia P, Aiello LP, Ishii H, et al. Characterization of vascular endothelial growth factor's effect on the activation of protein kinase C, its isoforms, and endothelial cell growth. J Clin Invest 1996; 98: 2018-2026.
206. Aiello LP, Bursell SE, Clermont A, et al. Vascular endothelial growth factor-induced retinal permeability is mediated by protein kinase C in vivo and suppressed by an orally effective beta-isoform-selective inhibitor. Diabetes 1997; 46: 1473-1480.
207. Suzuma K, Takahara N, Suzuma I, et al. Characterization of protein kinase C beta isoform's action on retinoblastoma protein phosphorylation, vascular endothelial growth factor-induced endothelial cell proliferation, and retinal neovascularization. Proc Natl Acad Sci USA 2002; 99: 721-726.
208. Wang A, Nomura M, Patan S, et al. Inhibition of protein kinase Calpha prevents endothelial cell migration and vascular tube formation in vitro and myocardial neovascularization in vivo. Circ Res 2002; 90: 609-616.
209. Brose N, Rosenmund C. Move over protein kinase C, you've got company: alternative cellular effectors of diacylglycerol and phorbol esters. J Cell Sci 2002; 115: 4399-4411.
210. Jones DR, Sanjuan MA, Stone JC, et al. Expression of a catalytically inactive form of diacylglycerol kinase alpha induces sustained signaling through RasGRP. FASEB J 2002; 16: 595-597.
211. Song Y, Ailenberg M, Silverman M. Human munc13 is a diacylglycerol receptor that induces apoptosis and may contribute to renal cell injury in hyperglycemia. Mol Biol Cell 1999; 10: 1609-1619.
212. Hall JL, Matter CM, Wang X, et al. Hyperglycemia inhibits vascular smooth muscle cell apoptosis through a protein kinase C-dependent pathway. Circ Res 2000; 87: 574-580.
213. Hammes HP, Du X, Edelstein D, et al. Benfotiamine blocks three major pathways of hyperglycemic damage and prevents experimental diabetic retinopathy. Nat Med 2003; 9: 294-299.
214. Milton RC, Aiello LP, Davis MD, et al. Initial results of the protein kinase Cβ inhibitor diabetic retinopathy study(PKC-DRS). Diabetes 2003; E-abstract:544-P.